Trial Profile
A Randomized, Double-blind, Sponsor Un-blinded, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 30 Mar 2020 Primary endpoint (Change from Baseline in the diffusing capacity of the lung for carbon monoxide on pulmonary gas transfer after 7 days of treatment) has not been met, according results published in the European Journal of Heart Failure
- 30 Mar 2020 Results published in the European Journal of Heart Failure
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.